Search the Newsreel

IMTX|Immatics NV|Price:8.660|Chg%:-0.540

This article provides an in-depth analysis of Immatics NV (IMTX) stock, including real-time quotes, key financial figures, and market trends. It highlights the company's strong fundamentals, high growth potential, and "Strong Buy" analyst ratings with significant upside potential. The report also details Immatics NV's …

Immatics NV (IMTX) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis of Immatics NV (IMTX), noting its current valuation score of 6.90 within the Biotechnology & Medical Research industry. It highlights the company's current P/E ratio of -12.17, which is significantly below its recent high and above its recent …

Immatics Number of Employees 2026 | Employee Count & Headcount Data

Immatics NV (NASDAQ: IMTX) had 426 employees worldwide as of March 2026, representing a 54.3% growth from 2023. The company, headquartered in Germany, is actively hiring with 45 job postings in 2026 and its workforce is primarily concentrated in Germany and the United States. …

Immatics (IMTX) general counsel Pepin Nelson reports insider status

Immatics N.V. (IMTX) general counsel and corporate secretary Pepin James Nelson has filed an initial statement of beneficial ownership (Form 3), establishing his insider status. The filing indicates no reported equity or derivative transactions, classifying him as an officer-reporting person. The document also notes …

Immatics NV (IMTX) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Immatics NV (IMTX), detailing its price momentum, support and resistance levels, and various technical indicators and moving averages. As of the analysis, the stock trades between support at 7.64 and resistance at 10.36, with a current price …

Immatics N.V. (NASDAQ:IMTX) Given Consensus Rating of "Moderate Buy" by Analysts

Eight analysts covering Immatics N.V. (NASDAQ:IMTX) have issued a "Moderate Buy" consensus rating, with six recommending a buy, one a hold, and one a sell. The average 12-month price target is $20.80, significantly above the current $9.08 share price, and institutional investors own 64.41% …

Troluce Capital Advisors LLC Acquires Shares of 250,000 Immatics N.V. $IMTX

Troluce Capital Advisors LLC recently acquired 250,000 shares of Immatics N.V. (NASDAQ:IMTX) for approximately $2.46 million, establishing a new position in the company. Despite Immatics missing Q1 analyst estimates for revenue and EPS, and receiving mixed analyst ratings with some recent downgrades, the consensus …

IMTX|Immatics NV|Price:8.800|

This article from TradingKey provides a comprehensive stock analysis of Immatics NV (IMTX), highlighting its strong fundamentals, significant growth potential, and "fairly valued" status within the Biotechnology & Medical Research industry. It notes high institutional ownership and multiple "Buy" ratings from analysts, despite a …

Immatics NV (IMTX) Shareholder Structure: Major Shareholders & Institutional Holdings

This article details the shareholder structure of Immatics NV (IMTX), listing its major shareholders and their proportional holdings. It also provides a breakdown of shareholder types, institutional shareholding data over several quarters, and recent shareholder activity from key investors. Additionally, the article identifies related …

Immatics NV (IMTX) Dividends & Stock Splits: Historical Payouts and Event Timeline

This article provides details on the dividend and stock split history for Immatics NV (IMTX). It indicates that the company has not distributed any dividends over the past five years. The page displays various financial metrics for IMTX, including its market capitalization, and stock …

Immatics NV (IMTX) Cash Flow

This article provides a detailed cash flow statement for Immatics NV (IMTX), broken down by operating, investing, and financing activities on both quarterly and annual bases. It includes financial figures, year-over-year changes, and a section of FAQs defining cash flow terms and summarizing Immatics …

Immatics N.V. Revenue Breakdown – NASDAQ:IMTX

Immatics N.V. (NASDAQ:IMTX) reported a revenue of $56.73 million USD last year. The majority of this revenue, $54.47 million USD, was generated by its PRAME-directed Immunotherapies segment, primarily from the United States. This represents a significant decrease compared to the previous year's total revenue …

IMTX|Immatics NV|Price:9.080|Chg%:-0.210

Immatics NV is a Netherlands-based clinical-stage biopharmaceutical company focused on developing T-Cell receptor immunotherapies for solid tumors. The company employs two therapeutic modalities: Adoptive Cell Therapies (ACT) and antibody-like TCR Bispecifics (TCER), with several programs in clinical trials and preclinical development. Its executive team …

TradingKey

This article provides a detailed quarterly and annual income statement for Immatics NV (IMTX), offering insights into the company's financial performance and operational efficiency. It presents data spanning several years for various financial metrics such as total revenue, operating expenses, net income, and earnings …

Immatics NV : Leerink Partners Assumes Covera

Leerink Partners has initiated coverage on Immatics NV (IMTX) with an "Outperform" rating, setting a target price of $16. The financial firm's assessment suggests a positive outlook for the company's stock performance. This information is provided for informational and educational purposes only and does …

Immatics stock trades steady as pipeline and cash position frame biotech outlook

Immatics stock (IMTX) reflects the balance between its Nasdaq-listed immunotherapy pipeline progress and a solid cash position. The company, a clinical-stage oncology biotech, relies on funding and partnerships, with recent financials highlighting collaboration revenue, research and development spending, and a multi-year cash runway. Investors …

Immatics N.V. (IMTX) Q1 2026 Earnings: EPS Miss Reflected in Wider Loss, Yet Stock Rises on Pipeline Progress - Share Repurchase Impact

Immatics to present PRAME cell therapy anzu-cel Phase 1b melanoma data at ESMO 2026

Immatics plans to present new Phase 1b data for its lead PRAME cell therapy, anzu-cel, in metastatic cutaneous and uveal melanoma at the ESMO Congress 2026. The presentation will focus on predictors of durable response. Additionally, the company will share Phase 1 results for …

Immatics’ three ESMO presentations span melanoma and solid tumors

Immatics (NASDAQ: IMTX) announced it will present three times at the ESMO Congress 2026, showcasing data from its PRAME-targeted pipeline, including lead cell therapies anzu-cel and IMA203CD8, and bispecific candidate IMA402. These presentations will cover Phase 1/1b trials across various solid tumors like advanced …

Immatics Announces Three ESMO 2026 Presentations Highlighting PRAME Cell Therapy and Bispecific Pipeline

Immatics N.V. (IMTX) will present three key sets of data at the European Society for Medical Oncology (ESMO) Congress 2026, showcasing its PRAME-targeting therapies, including Phase 1b data for anzu-cel in metastatic melanoma, Phase 1 data for IMA203CD8 in various solid tumors, and Phase …

Immatics Announces Upcoming Presentations Across Its PRAME Franchise at ESMO Congress 2026

Immatics N.V. announced three presentations at the European Society for Medical Oncology (ESMO) Congress 2026, showcasing data from its PRAME franchise. These presentations will include Phase 1b data for anzu-cel in advanced melanoma, Phase 1 data for IMA203CD8 in various PRAME-positive solid tumors, and …